Has anybody given a thought to the fact that OPK is neither a boon to the longs or to the shorts (talking about the very short term here)? Time will fix that for the longs, but in the meantime the shorts are paying hefty interest each month on their stagnant position. The more they short to keep the price down, the higher the interest goes as the available shares to short dwindle.
To add insult to injury, Frost is buying the shares they short. I read somewhere that Frost is something of a poker player. So........how's this for a nightmare.......you're in a poker game with a billionaire. Probably not smart. FWIW
Yah, web sites are the bomb. Here's one for you to use if you want to know if Sanofi people are on board with Afrezza:
It's up to you to learn how to navigate the site, but I assure you they are talking about it (they being the sales people). FWIW
No, no.........that's only what they are like when it comes to paying claims. He hee.
Given that they are all for-profit companies (unlike the gummint), with quarterly reports and shareholders (not to mention bonuses and stock options), cutting costs gets a front row seat.
Insurance covers biopsies. It covers complications (hospitalization) due to complications of biopsies. If 4Kscore can reduce the number of biopsies by 40-50%, and you're the insurance company, do you cover 4Kscore? Whatever you might think of insurance companies, they are not stupid. FWIW
OPKO Launches the 4Kscore Test in Europe
OPKO Health, Inc. (NYSE:OPK) today announced the European launch of the 4Kscore ™ Test, the only blood test that accurately identifies risk for aggressive prostate cancer, through its wholly owned subsidiary, OPKO Health Spain. The launch in Europe follows the U.S. launch of the 4Kscore earlier this year.
The 4Kscore is a blood test that provides a patient his individualized risk for aggressive prostate cancer. The panel of biomarkers utilized in the 4Kscore is based on over a decade of clinical research conducted in Europe by investigators from Memorial Sloan-Kettering Cancer Center and leading European medical institutions involving over 10,000 patients. The 4Kscore Test was developed and validated by OPKO Lab in a 1,012 patient blinded, prospective study in the U.S. in 2014. “We are proud to now offer the 4Kscore Test to European clinicians and patients,” said Julián Agut Sánchez, CEO of OPKO Health Europe. “The 4Kscore will bring exceptional value to European healthcare by allowing clinicians to accurately identify risk for aggressive prostate cancer. In addition, there is great benefit for the patients and the healthcare systems in avoiding the cost of unnecessary, sometimes harmful procedures.”
The European launch of the 4Kscore Test is being done in partnership with Barnaclínic, a branch of Hospital Clínic de Barcelona, one of the most modern and largest clinical laboratories in Europe. “The 4Kscore Test represents the new direction we must follow in clinical medicine by combining multiple biomarkers for greater diagnostic accuracy and delivering the results to the clinician in an easy to interpret report,” said Aurea Mira Vallet, Manager of the Diagnostic Biomedical Center, Hospital Clínic de Barcelona. “We look forward to our partnership with OPKO on the 4Kscore Test and helping European Urologists to more accurately identify risk for aggressive prostate cancer.”
Prostate cancer is the most common c
Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference
OPKO Health, Inc. (NYSE: OPK), today announced that the abstract “Top Line Results of Once-Weekly, CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency (GHD)” has been selected for late breaking oral presentation at the 53rd Annual Meeting of the European Society of Paediatric Endocrinology (ESPE) on September 20, 2014 in Dublin, Ireland. OPKO will present six month efficacy, safety, pharmacokinetic and pharmacodynamics data from the company's advanced phase 2 trial for its long acting human growth hormone hGH-CTP (MOD-4023) in growth hormone deficient pediatric subjects.
In addition, OPKO’s posters to be presented during the conference have been recognized for outstanding advancement by ESPE and will introduce additional data, as well as analytical characteristics of hGH-CTP in preparation for the planned pediatric phase 3 study.
The data to be presented include results from the company’s phase 2 trial, a one year dose finding study administering hGH-CTP to growth hormone deficient children once a week using daily hGH as a comparator. The data from this study supported once-weekly dosing for hGH-CTP and also enabled the selection of an appropriate dose to demonstrate non-inferiority compared to daily hGH in the upcoming phase 3 study. hGH-CTP demonstrated a good safety and tolerability profile in this ongoing study.
OPKO presentations include the following:
Oral Communication: “Top Line Results of Once-Weekly, CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency (GHD)
Session details: FC – Late Breaking; Saturday September 20, 2014 08:45 – 09:45
Poster P1-D3-163 Six month Follow-up Pharmacokinetics and Pharmac
"But given how the market works, we all know that it always responds to events 6 months to a year BEFORE those events happen."
My advice would be to rid yourself of those out-dated text books. The market does not work on fundamentals for the majority of stocks anymore. Haven't you been keeping up? You got your algo boxes that sniff headlines (such as Putin said this, or Obama said that, or some nobody on some web site said something else), which is coupled with collocated servers and fat pipes and nano-second trading.......not to mention a hundred types of buy/sell orders you have never seen).
Get yourself updated, young man, and then ask a serious question. Or, if you're just a troll, go away.
People who appreciate that kind of humor care. I had a good laugh.
He's going to sell them slowly......at a loss. That's what he said. Now either the price will go down more, and his loss will increase, or the price will go up, and he will do what most retail people do who bought at the top........sell at the bottom just as price is ready to move up. Either way, that there is funny..........I don't care who you are. LOL.
It's fixin' to start. :-) Milestone payment happens upon ACCEPTANCE of NDA by the FDA.
Yeah. Given your screen name, why not take AAPL private? Why not MSFT? Hell, why not the whole damned market?
"If all you have is a hammer, everything is a nail."